News & Events
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
WATERTOWN, Mass., June 12, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that
More News
Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week
WATERTOWN, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...
read more
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer
Dr. Steve Caffé is an accomplished industry executive with over 25 years of expertise in global product development and regulatory affairs WATERTOWN,...
read more
Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update
Presented positive data for all three programs at the European Hematology Association (EHA) 2024 Congress; demonstrated potential efficacy for bitopertin in erythropoietic...
read more